Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Occupational therapy vs usual care

Community integration · adults with cognitive impairment after stroke

1 finding from 1 review

Occupational therapy for cognitive impairment in stroke patients 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 78 participants
Low

Occupational therapy vs usual care

4a. Global cognitive functional performance (sensitivity analysis) (postintervention) · adults with cognitive impairment after stroke

1 finding from 1 review

Occupational therapy for cognitive impairment in stroke patients 2022 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 432 participants
Low

Occupational therapy vs usual care

Attention · adults with cognitive impairment after stroke

1 finding from 1 review

Occupational therapy for cognitive impairment in stroke patients 2022 · Cochrane Headline outcomes only
no estimate extracted
5 participants
GRADE not reported

Antiplatelet therapy vs placebo

Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antiplatelet therapy vs placebo

Functional ability · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Withdrawal from study medication · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Cognitive function · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Incidence of dementia · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombolytic therapy vs heparin: primary outcome measures

Death from all causes (duration of · patients with acute pulmonary embolism

Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).

1 finding from 1 review

Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
OR 0.58 [0.38, 0.88]
19 studies · 2319 participants
Low

Thrombolytic therapy vs heparin: primary outcome measures

Recurrence of pulmonary emboli · patients with acute pulmonary embolism

Thrombolytic therapy may leads to lower recurrence of pulmonary emboli (duration of compared with heparin: primary outcome measures (low certainty).

1 finding from 1 review

Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
OR 0.54 [0.32, 0.91]
12 studies · 2050 participants
Low

Thrombolytic therapy vs heparin: primary outcome measures

Major bleeding · patients with acute pulmonary embolism

Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).

1 finding from 1 review

Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
OR 2.84 [1.92, 4.2]
15 studies · 2101 participants
Moderate

Thrombolytic therapy vs heparin: primary outcome measures

Minor haemorrhagic events (duration of · patients with acute pulmonary embolism

Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).

1 finding from 1 review

Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
OR 2.97 [1.66, 5.3]
13 studies · 1757 participants
Low

Reminiscence therapy vs no treatment

Quality of Life: self‐report · people with dementia

1 finding from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1060 participants
Moderate

Reminiscence therapy vs no treatment

Individual: communication at end of treatment · people with dementia

1 finding from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 96 participants
Very low

Reminiscence therapy vs no treatment

Group: quality of life (self‐reported) at end of treatment · people with dementia

1 finding from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1037 participants
High

Reminiscence therapy vs no treatment

Cognition at end of treatment · people with dementia

3 findings from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1023 participants
High
Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 989 participants
High
Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 1219 participants
High

Reminiscence therapy vs no treatment

Group: communication at end of treatment · people with dementia

1 finding from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 153 participants
Moderate

Reminiscence therapy vs no treatment

Care home: quality of life (self‐reported) at end of treatment · people with dementia

1 finding from 1 review

Reminiscence therapy for dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 193 participants
Moderate